Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. - Wikidata - awgldk - TriplyDB

Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.

Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.

http://www.wikidata.org/entity/Q33292125

about

A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population Molecular genetics of coronary artery disease Advances in the genetic basis of coronary artery disease High shear stress induces atherosclerotic vulnerable plaque formation through angiogenesis Natural single amino acid polymorphism (F19Y) in human galectin-8: detection of structural alterations and increased growth-regulatory activity on tumor cells Human galectin-2 interacts with carbohydrates and peptides non-classically: new insight from X-ray crystallography and hemagglutination PADB: published association database Long-term outdoor air pollution and DNA methylation in circulating monocytes: results from the Multi-Ethnic Study of Atherosclerosis (MESA)Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury via TNF receptor 1, but are cardioprotective when activating TNF receptor 2 Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study Genome-wide association study of coronary artery disease in the Japanese IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation.Polymorphism in the MHC2TA gene is associated with features of the metabolic syndrome and cardiovascular mortality.Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes.Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans Endothelial galectin-1 binds to specific glycans on nipah virus fusion protein and inhibits maturation, mobility, and function to block syncytia formation.Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships Recent developments in genomewide association scans: a workshop summary and review A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study Interrelationships between ALOX5AP polymorphisms, serum leukotriene B4 level and risk of acute coronary syndrome Genome-wide association study of coronary artery disease.Association between LGALS2 3279C>T and coronary artery disease: A case-control study and a meta-analysis.A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults.Platelets and galectins Lack of association between LTA and LGALS2 polymorphisms and myocardial infarction in Japanese and Korean populations.Genetics of stress response and stress-related disorders.Genetic association study of coronary collateral circulation in patients with coronary artery disease using 22 single nucleotide polymorphisms corresponding to 10 genes involved in postischemic neovascularization.The genetics of heart attack Genomic and proteomic determinants of lower extremity revascularization failure: rationale and study design Regulatory roles of galectins in the immune response.Galectins as self/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox.Galectins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease.Genetic and genomic insights into the molecular basis of atherosclerosis.Genetic markers of cardiovascular disease in rheumatoid arthritis.When galectins recognize glycans: from biochemistry to physiology and back again The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders.Calycosin‑7‑O‑β‑D‑glucoside attenuates ischemia‑reperfusion injury in vivo via activation of the PI3K/Akt pathway.Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better?Genetic susceptibility to myocardial infarction and coronary artery disease.Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.

P2860

5e2e40e07146bff86c9ae91f1a9e0e8e35a0f095

P248

Q24297364-0EA5F5FC-9A45-4F50-A8F6-B1F7EDFAC19F Q24674808-0445354B-A36D-4F05-A6C3-27B88C0A700E Q24682029-C51D6055-2F7B-49F0-A3BC-6BA552219A9B Q26740033-1BBAF228-830B-4F12-A49C-FF57DF3B46C0 Q27688879-164EC9A6-B5A1-4FBE-8DE6-38B439EE0905 Q27727738-1454BD29-62BF-46EE-AB26-7557560B7B4D Q28221773-0D52454F-BB3A-44D7-AD17-76E610330B76 Q28395480-B36C160B-57DC-4AD4-A1E5-F8A79C511538 Q28488447-DD89D4C5-4D7C-41EC-BD58-1E9A8AF9732D Q28943280-89E40BE9-3698-44C5-B7DD-D9D3B33863E2 Q28943353-9674B250-FB6F-4280-AF5D-95F1C776CA26 Q30448616-4F4DBBA1-443E-4D21-B945-E893DB32AFE7 Q33267324-AEF4B1CF-DDFD-404C-B9FB-5C15E068731F Q33300816-DB3F26DA-74FF-444A-963A-16362BEC8F85 Q33586454-6437767A-450B-4B3C-8A04-DBE1EFD3B683 Q33640112-51401C0E-DCD4-44DB-9A4A-7BE70B4E391C Q33689539-BAD77ABB-A4BF-4651-9980-F9F700E89879 Q34021104-3F664EB8-B895-42ED-A095-FC5DD978E346 Q34137411-596CC373-9584-4532-B2E0-C8412871C8F6 Q34165844-B26166B8-E682-418F-9BF4-CF51C31CF197 Q34218772-F3A32BC7-E1C5-4C24-94BF-2FC89F17E62C Q34265297-7193B272-3091-4F98-9DB0-C2754BA8ABC2 Q34297619-73C5791E-0608-4F04-B633-AB5B735126E5 Q34385152-A96662A5-8320-4EAE-8D91-C32F33550ABF Q34627081-AD925470-1EDD-4837-861B-E1020CB25CA2 Q35236890-CB930922-AC5E-4A9D-B38C-C6052F124148 Q35626327-8BE95A81-92C7-4287-BFBD-CA4FE87F0025 Q35770844-8C208E65-824C-4CA5-8B27-45624FC112CF Q35944843-4222C379-4D19-43A2-8864-2FA42A8F08B2 Q36073653-CF745258-4E67-49D8-A2BF-658994E134BD Q36093631-58F1A0E8-D3D9-45A5-8740-B50428400BBC Q36135442-00F6408D-0EDD-4F0E-8452-83D62E3D7176 Q36155114-08350E7E-5F65-4798-A806-54A3C6470447 Q36165202-AFD2E438-E51A-4ABA-A0BA-A87C2E1360D9 Q36196146-B8CFC0B1-A0A2-45D5-BC87-4B9831D20367 Q36292670-4B1D9C5C-72BD-4677-A2A5-DD7C6828B2C6 Q36390251-8A1AEA6F-30DC-4F02-8F2F-D27786964718 Q36580332-2DDBF34F-F2C5-443D-A7AF-BDBFCA5E608C Q36599259-FE80C49B-9CF8-4D3F-BFD3-18E7D6403E49 Q36741513-45EA86BB-171F-4419-8019-E95441DD5ADB

P2860

Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.

http://www.wikidata.org/entity/Q33292125

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@ast

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@en

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@nl

type

label

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@ast

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@en

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@nl

prefLabel

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@ast

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@en

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@nl

P1433

Q33292125-5A4F8580-5071-455A-AE5A-557D47078334

P1476

Q33292125-FA8B9ABF-4797-4F76-BBD1-C2351913A79A

P2093

Q33292125-08DC58DA-6178-4C4F-B092-10D45A723E55

Q33292125-16100970-A096-43F7-957E-FA41A36F37CE

Q33292125-32BDEC7C-733E-45BE-80BB-5BEF1B1E3745

Q33292125-36D04A80-812F-415C-9B0A-1A74D3FACD5B

Q33292125-5495EF40-2D42-436C-8E37-5E441F27AD4D

Q33292125-8C5F4A35-4E0D-4E64-B170-1B21859DBB6E

Q33292125-B4ECCB80-BF9B-47F0-AF4B-EEE333226851

Q33292125-B7261E5D-3242-49E5-A7AA-EEAC7268A385

Q33292125-DA8EC4E8-D6F7-4E31-9E9B-823E80B68FE0

P2888

Q33292125-B3459AD5-5EAF-499B-9B1B-A63EA3ED409D

P304

Q33292125-078861D4-11CF-4C1B-887C-746607113229

P31

Q33292125-1AE4BDF0-485B-44D5-AAD5-0686D3897578

P356

Q33292125-F2F27032-7A32-4A6D-833B-825FE516CB95

P407

Q33292125-4F3FB38C-9CC5-48AD-AF96-C84811A23CD1

P433

Q33292125-0779E8D3-056C-44BC-B8E7-28EBF81C9425

P478

Q33292125-3EEE13D1-B797-418A-B4D9-BBD10879B7A9

P50

Q33292125-252EC911-F204-4D30-A3C9-78140F26DC5E

Q33292125-560D686B-334D-4A45-B52E-C5579789FF39

Q33292125-79804C6F-034E-45F2-9154-A027A01CB6A0

P577

Q33292125-704F3817-D449-45F7-A288-9AF869749072

P5875

Q33292125-F1EE34B5-0155-4BA8-A1F2-59EB66A20867

P6179

Q33292125-1EF4D1B7-6D26-483C-AB78-B42D7979B947

P698

Q33292125-6F7D4868-9B88-4C2D-B416-405946CC59B3

P921

Q33292125-0E35C5A5-6FE0-4007-8F10-66F6A8AAC36C

P356

P1433

P1476

Functional variation in LGALS2 ...... oxin-alpha secretion in vitro.

@en

P2093

Akihiro Sekine

http://www.w3.org/2001/XMLSchema#string

Aritoshi Iida

http://www.w3.org/2001/XMLSchema#string

Hideyuki Sato

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sato

http://www.w3.org/2001/XMLSchema#string

Katsumi Inoue

http://www.w3.org/2001/XMLSchema#string

Masakiyo Nobuyoshi

http://www.w3.org/2001/XMLSchema#string

Masatsugu Hori

http://www.w3.org/2001/XMLSchema#string

Yozo Ohnishi

http://www.w3.org/2001/XMLSchema#string

Yusuke Nakamura

http://www.w3.org/2001/XMLSchema#string

P2888

P304

72-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE02502

http://www.w3.org/2001/XMLSchema#string

P407

P433

6987

http://www.w3.org/2001/XMLSchema#string

P478

429

http://www.w3.org/2001/XMLSchema#string

P50

Toshihiro Tanaka

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232789814

http://www.w3.org/2001/XMLSchema#string

P6179

1019091080

http://www.w3.org/2001/XMLSchema#string

P698

15129282

http://www.w3.org/2001/XMLSchema#string

P921